Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Abstract Background Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads.Patients and methods Patients were included in a single arm protocol to receive 600mg of hydroxychloroquine daily and their viral load in nasal swabs was tested daily. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point.Results Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.Conclusion Hydroxychloroquine is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
bioRxiv.org - (2020) vom: 28. Dez. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gautret, Philippe [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.03.16.20037135 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI000808253 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI000808253 | ||
| 003 | DE-627 | ||
| 005 | 20230429092431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200327s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.03.16.20037135 |2 doi | |
| 035 | |a (DE-627)XBI000808253 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.03.16.20037135 | ||
| 035 | |a (biorXiv)10.1101/2020.03.16.20037135 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Gautret, Philippe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads.Patients and methods Patients were included in a single arm protocol to receive 600mg of hydroxychloroquine daily and their viral load in nasal swabs was tested daily. Depending on their clinical presentation, azithromycin was added to the treatment. Untreated patients from another center and cases refusing the protocol were included as negative controls. Presence and absence of virus at Day6-post inclusion was considered the end point.Results Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to hydroxychloroquine was significantly more efficient for virus elimination.Conclusion Hydroxychloroquine is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin. | ||
| 700 | 1 | |a Lagier, Jean-Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Parola, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Hoang, Van Thuan |e verfasserin |4 aut | |
| 700 | 1 | |a Meddeb, Line |e verfasserin |4 aut | |
| 700 | 1 | |a Mailhe, Morgane |e verfasserin |4 aut | |
| 700 | 1 | |a Doudier, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Courjon, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Giordanengo, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Vieira, Vera Esteves |e verfasserin |4 aut | |
| 700 | 1 | |a Dupont, Hervé Tissot |e verfasserin |4 aut | |
| 700 | 1 | |a Honoré, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Colson, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Chabrière, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Scola, Bernard La |e verfasserin |4 aut | |
| 700 | 1 | |a Rolain, Jean-Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Brouqui, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Raoult, Didier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2020) vom: 28. Dez. |
| 773 | 1 | 8 | |g year:2020 |g day:28 |g month:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijantimicag.2020.105949 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.03.16.20037135 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 28 |c 12 | ||
| 953 | |2 045F |a 570 | ||